May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Vitreous Levels of CX3C Chemokine, Fractalkine, in Vitreoretinal Diseases
J. You; C.–H. Yang; J.–S. Huang; M.–S. Chen
Author Affiliations & Notes
  • J. You
    Dept of Ophthalmology, Keelung General Hospital, Department of Health, the Executive Yuan, Keelung, Taiwan Republic of China
  • C.–H. Yang
    Dept of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan Republic of China
  • J.–S. Huang
    Dept of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan Republic of China
  • M.–S. Chen
    Dept of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan Republic of China
  • Footnotes
    Commercial Relationships  J. You, None; C. Yang, None; J. Huang, None; M. Chen, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2496. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Vitreous Levels of CX3C Chemokine, Fractalkine, in Vitreoretinal Diseases
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J. You, C.–H. Yang, J.–S. Huang, M.–S. Chen; Vitreous Levels of CX3C Chemokine, Fractalkine, in Vitreoretinal Diseases . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2496.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: Chemokines play an important role in the pathogenesis of ocular inflammation and angiogenesis. Fractalkine, the CX3C chemokine, has been reported to be expressed in various ocular tissues and inflammatory mediators can modulate ocular fractalkine expression. To further understanding the role of fractalkine in ocular disorders, in this study, the vitreous levels of fractalkine were determined in various vitreoretinal diseases. Methods: Twenty–one subjects with proliferative diabetic retinopathy (PDR), six subjects with rhegmatogenous retinal detachment (RRD) and seven control subjects including 4 idiopathic epiretinal membrane and 3 idiopathic macular hole were enrolled. Vitreous samples were collected during pars plana vitrectomy. Fractalkine levels in vitreous were measured by enzyme–linked immunosorbent assay. Results: The vitreous levels of fractalkine both in the PDR group (3.42 + 2.03 ng/ml) and in the RRD group (3.93 + 2.76 ng/ml) were significantly higher than in control subjects (1.66 + 1.79 ng/ml) (Mann–Whitney U test, P = 0.032 and P= 0.002, respectively). No significant difference between PDR group and RD group was found (P= 0.57). Conclusions: In this study, elevated vitreous levels of fractalkine were noted in eyes with PDR and RRD. Fractalkine might play an important role in the pathogenesis of ocular angiogenetic diseases and proliferative vitreoretinopathy.

Keywords: cytokines/chemokines • proliferative vitreoretinopathy • diabetic retinopathy 
© 2004, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept